153 related articles for article (PubMed ID: 26414241)
1. Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent: insights on the inhibition mechanism in acidic pH.
Hoelz LV; Leal VF; Rodrigues CR; Pascutti PG; Albuquerque MG; Muri EM; Dias LR
J Biomol Struct Dyn; 2016 Sep; 34(9):1969-78. PubMed ID: 26414241
[TBL] [Abstract][Full Text] [Related]
2. First quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones.
Arafet K; Ferrer S; Moliner V
Biochemistry; 2015 Jun; 54(21):3381-91. PubMed ID: 25965914
[TBL] [Abstract][Full Text] [Related]
3. Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases.
Silva LR; Guimarães AS; do Nascimento J; do Santos Nascimento IJ; da Silva EB; McKerrow JH; Cardoso SH; da Silva-Júnior EF
Bioorg Med Chem; 2021 Jul; 41():116213. PubMed ID: 33992862
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain.
Huang L; Brinen LS; Ellman JA
Bioorg Med Chem; 2003 Jan; 11(1):21-9. PubMed ID: 12467703
[TBL] [Abstract][Full Text] [Related]
5. Dissecting a novel allosteric mechanism of cruzain: A computer-aided approach.
Hernández Alvarez L; Barreto Gomes DE; Hernández González JE; Pascutti PG
PLoS One; 2019; 14(1):e0211227. PubMed ID: 30682119
[TBL] [Abstract][Full Text] [Related]
6. Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles.
Dos Santos AM; Cianni L; De Vita D; Rosini F; Leitão A; Laughton CA; Lameira J; Montanari CA
Phys Chem Chem Phys; 2018 Sep; 20(37):24317-24328. PubMed ID: 30211406
[TBL] [Abstract][Full Text] [Related]
7. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
8. Novel cruzain inhibitors for the treatment of Chagas' disease.
Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Scheidt KA; Roush WR; McKerrow JH; Selzer PM; Hansell E; Rosenthal PJ
Bioorg Med Chem; 1998 Dec; 6(12):2477-94. PubMed ID: 9925304
[TBL] [Abstract][Full Text] [Related]
10. Study of the dynamic behavior of the cruzain enzyme in free and complexed forms with competitive and noncovalent benzimidazole inhibitors.
Reis CRCD; Souza HVCM; Leme RPP; Castelo-Branco FS; Fernandes TVA; Boechat N; Dias LRS; Hoelz LVB
J Biomol Struct Dyn; 2023 Jul; 41(10):4368-4382. PubMed ID: 35475501
[TBL] [Abstract][Full Text] [Related]
11. Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors.
Cianni L; Sartori G; Rosini F; De Vita D; Pires G; Lopes BR; Leitão A; Burtoloso ACB; Montanari CA
Bioorg Chem; 2018 Sep; 79():285-292. PubMed ID: 29783099
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
de Souza ML; de Oliveira Rezende Junior C; Ferreira RS; Espinoza Chávez RM; Ferreira LLG; Slafer BW; Magalhães LG; Krogh R; Oliva G; Cruz FC; Dias LC; Andricopulo AD
J Chem Inf Model; 2020 Feb; 60(2):1028-1041. PubMed ID: 31765144
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
Mott BT; Ferreira RS; Simeonov A; Jadhav A; Ang KK; Leister W; Shen M; Silveira JT; Doyle PS; Arkin MR; McKerrow JH; Inglese J; Austin CP; Thomas CJ; Shoichet BK; Maloney DJ
J Med Chem; 2010 Jan; 53(1):52-60. PubMed ID: 19908842
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of chagasin, the endogenous cysteine-protease inhibitor from Trypanosoma cruzi.
Figueiredo da Silva AA; de Carvalho Vieira L; Krieger MA; Goldenberg S; Zanchin NI; Guimarães BG
J Struct Biol; 2007 Feb; 157(2):416-23. PubMed ID: 17011790
[TBL] [Abstract][Full Text] [Related]
16. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the binding mode of a novel cruzain inhibitor by docking, molecular dynamics, ab initio and MM/PBSA calculations.
Martins LC; Torres PHM; de Oliveira RB; Pascutti PG; Cino EA; Ferreira RS
J Comput Aided Mol Des; 2018 May; 32(5):591-605. PubMed ID: 29564808
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new class of nonpeptidic inhibitors of cruzain.
Brak K; Doyle PS; McKerrow JH; Ellman JA
J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
[TBL] [Abstract][Full Text] [Related]
19. Mapping inhibitor binding modes on an active cysteine protease via nuclear magnetic resonance spectroscopy.
Lee GM; Balouch E; Goetz DH; Lazic A; McKerrow JH; Craik CS
Biochemistry; 2012 Dec; 51(50):10087-98. PubMed ID: 23181936
[TBL] [Abstract][Full Text] [Related]
20. Cruzain structures: apocruzain and cruzain bound to S-methyl thiomethanesulfonate and implications for drug design.
Barbosa da Silva E; Dall E; Briza P; Brandstetter H; Ferreira RS
Acta Crystallogr F Struct Biol Commun; 2019 Jun; 75(Pt 6):419-427. PubMed ID: 31204688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
